Astrinidis Research Lab
  • Home
  • What is TSC and LAM?
    • TSC and LAM
    • Rapamycin treatment
  • Research
    • Background
    • Current projects
    • Funding
    • Publications
  • Positions
  • About
    • Lab members
    • Collaborators
    • Contact
    • Disclaimer

TSC and LAM at a glance

Tuberous Sclerosis Complex (TSC)
  • Incidence: 1 in 5,800
  • Number of patients: 75-100 thousand in the US, 1.2-1.5 million world-wide
  • Organs affected primarily: brain, skin, kidneys, lungs
  • Cause: mutations in TSC1 and TSC2, hyperactivation of mTOR

Sporadic Lymphangioleiomyomatosis (LAM)
  • Incidence 3-5 per million
  • Number of patients: 1,000-1500 in the US, 20-40 thousand worldwide 
  • Organs affected: lungs, kidneys, lymphatics
  • Cause: mutations in TSC2, hyperactivation of mTOR
Updated 5 March 2018

Next topic: TSC and LAM in detail
Jump to Rapamycin treatment
© 2007-2016 Aristotelis Astrinidis, and the Astrinidis Lab | Disclaimer
Current projects | Lab Members | Contact
Proudly powered by Weebly